Search results
30 cze 2021 · Although targeted therapy has evolved in the last years and significantly improved the prognosis of patients with cutaneous melanoma, its use in vulvar and vaginal melanomas is still limited by the different mutagenic profiles involving fewer BRAF mutations and more c-KIT, NF1 and SF3B1 mutations [91,112]. Thus, monoclonal antibodies such as ...
1 paź 2024 · Survival in vulvar melanoma is superior to that of vaginal melanoma. • Most patients disease free five years after surgical resection received an adjuvant therapy. • Complete response to treatment of recurrence or progression was most frequent with nivolumab plus ipilimumab. • Overall survival for vulvar and vaginal melanomas did not ...
22 maj 2020 · Conclusions. Vulvar melanoma has a poor prognosis for those with regional and distant metastatic disease. Extent of disease, tumor size, and patient age are important prognostic factors. Other favorable factors included insurance and surgical management.
15 maj 2014 · Surgery is the preferred primary treatment for vulvovaginal melanoma, if feasible, and not requiring an exenterative procedure. The two main considerations in surgery are the management of the primary tumor and nodal assessment and management.
14 cze 2021 · Compared with skin melanomas, vulvar melanomas are associated with a poor prognosis resulting from delayed diagnosis and different tumor biology, treatment strategies, and treatment response. Novel treatment modalities include checkpoint inhibitors and targeted therapies and recent evidence shows that these are also effective in vulvar melanomas.
Most patients are treated with surgical resection with varying use of adjuvant radiotherapy. Further research is needed to identify the etiology and improve the outcome of this aggressive disease. https://doi.org/10.1097/IGC.0b013e3182a1ced8. Request Permissions.
Surgery is the preferred primary treatment for vulvovagi-nal melanoma, if feasible, and not requiring an exenterative procedure. The two main considerations in surgery are the management of the primary tumor and nodal assessment and management.
